FindTrial
Sign In

Myo-inositol Plus Melatonin in Perimenopausal Women

Effects of Myo-inositol Plus Melatonin in Perimenopausal Women

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01325389
Enrollment
Unknown
Registered
2011-03-29
Start date
Unknown
Completion date
Unknown
Last updated
2011-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perimenopause

Brief summary

Menopause is the milestone of a more broaden condition that can last up to 10 years. The first menopausal symptoms usually appear around the age of 42 and are characterized by a gradual decline in thyroid and gonadal function with a progressive increase of plasmatic luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels. Recent studies have shown that myo-inositol and melatonin play a major role in ovarian homeostasis. In particular, it has been demonstrated that myo-inositol and/or melatonin supplementation lead to an increase of oocyte quality. Additional studies focused on postmenopausal women have shown that myo-inositol is able to ameliorate the metabolic syndrome that often affects these patients, thus reducing the risk of cardiovascular diseases (CVDs). The aim of the present study is to evaluate whether myo-inositol and melatonin might play a positive role in regulating hormonal levels during menopausal onset.

Interventions

DIETARY_SUPPLEMENTMyo-Mel
DIETARY_SUPPLEMENTPlacebo

Sponsors

AGUNCO Obstetrics and Gynecology Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
42 Years to 48 Years
Healthy volunteers
Yes

Inclusion criteria

* FSH between 15 and 50 IU/ml on the 5th day of the menses * Oligomenorrhea

Exclusion criteria

\-

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026